beta-blocker treatment during pregnancy and adverse preagnancy outcomes: a nationwide population-based cohort study

Peter Meidahl Petersen; Espen Victor Jimenez Solem; Jon Trærup Andersen

doi:10.1136/bmjopen-2012-001185

beta-blocker treatment during pregnancy and adverse preagnancy outcomes: a nationwide population-based cohort study

Peter Meidahl Petersen, Espen Victor Jimenez Solem, Jon Trærup Andersen

80 Citations (Scopus)

Abstract

Objective: To investigate the association between exposure to β-blockers during pregnancy and the risk of being born small for gestational age (SGA), preterm birth and perinatal mortality in a nationwide cohort. Design: A population-based retrospective cohort study, using the Danish Fertility Database. The authors identified all pregnant women redeeming a prescription for β-blockers using the National Prescription Registry. Multivariate logistic regression models were used to assess the association between exposure and our outcomes. Setting: Register-based survey. Participants: 911'685 births between 1995 and 2008 obtained from the Danish Fertility Database. Outcome measures: Being born SGA was defined as having a birth weight below the 10th percentile for the corresponding gestational week. Preterm birth was defined as birth before the 37th gestational week. Perinatal mortality was defined as either death occurring within the first 28 days of life or stillbirth. Before 2004, fetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation, but since then stillbirth is recorded for deaths after 22 gestational weeks. Results: The authors identified 2459 pregnancies exposed to β-blockers. β-Blocker exposure during pregnancy was found to be associated with increased risk of SGA (adjusted OR 1.97, 95% CI 1.75 to 2.23), preterm birth (adjusted OR 2.26, 95% CI 2.03 to 2.52) and perinatal mortality (adjusted OR 1.89, 95% CI 1.25 to 2.84). Analyses were adjusted for socioeconomic and maternal variables. The authors found similar risk profiles for pregnancies exposed to labetalol and for pregnancies exposed to other β-blockers. Conclusions: The authors found that exposure to β-blockers during pregnancy was associated with being born SGA, preterm birth and perinatal mortality. Our findings show that labetalol is not safer than other β-blockers during pregnancy.

Original language	English
Journal	BMJ Open
Volume	2
Issue number	4
DOIs	https://doi.org/10.1136/bmjopen-2012-001185
Publication status	Published - 2012

Access to Document

10.1136/bmjopen-2012-001185

Cite this

@article{5811270feac744489073d962bdeea2ae,

title = "beta-blocker treatment during pregnancy and adverse preagnancy outcomes: a nationwide population-based cohort study",

abstract = "Objective: To investigate the association between exposure to β-blockers during pregnancy and the risk of being born small for gestational age (SGA), preterm birth and perinatal mortality in a nationwide cohort. Design: A population-based retrospective cohort study, using the Danish Fertility Database. The authors identified all pregnant women redeeming a prescription for β-blockers using the National Prescription Registry. Multivariate logistic regression models were used to assess the association between exposure and our outcomes. Setting: Register-based survey. Participants: 911'685 births between 1995 and 2008 obtained from the Danish Fertility Database. Outcome measures: Being born SGA was defined as having a birth weight below the 10th percentile for the corresponding gestational week. Preterm birth was defined as birth before the 37th gestational week. Perinatal mortality was defined as either death occurring within the first 28 days of life or stillbirth. Before 2004, fetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation, but since then stillbirth is recorded for deaths after 22 gestational weeks. Results: The authors identified 2459 pregnancies exposed to β-blockers. β-Blocker exposure during pregnancy was found to be associated with increased risk of SGA (adjusted OR 1.97, 95% CI 1.75 to 2.23), preterm birth (adjusted OR 2.26, 95% CI 2.03 to 2.52) and perinatal mortality (adjusted OR 1.89, 95% CI 1.25 to 2.84). Analyses were adjusted for socioeconomic and maternal variables. The authors found similar risk profiles for pregnancies exposed to labetalol and for pregnancies exposed to other β-blockers. Conclusions: The authors found that exposure to β-blockers during pregnancy was associated with being born SGA, preterm birth and perinatal mortality. Our findings show that labetalol is not safer than other β-blockers during pregnancy.",

author = "Petersen, {Peter Meidahl} and Solem, {Espen Victor Jimenez} and Andersen, {Jon Tr{\ae}rup}",

year = "2012",

doi = "10.1136/bmjopen-2012-001185",

language = "English",

volume = "2",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "4",

}

TY - JOUR

T1 - beta-blocker treatment during pregnancy and adverse preagnancy outcomes: a nationwide population-based cohort study

AU - Petersen, Peter Meidahl

AU - Solem, Espen Victor Jimenez

AU - Andersen, Jon Trærup

PY - 2012

Y1 - 2012

N2 - Objective: To investigate the association between exposure to β-blockers during pregnancy and the risk of being born small for gestational age (SGA), preterm birth and perinatal mortality in a nationwide cohort. Design: A population-based retrospective cohort study, using the Danish Fertility Database. The authors identified all pregnant women redeeming a prescription for β-blockers using the National Prescription Registry. Multivariate logistic regression models were used to assess the association between exposure and our outcomes. Setting: Register-based survey. Participants: 911'685 births between 1995 and 2008 obtained from the Danish Fertility Database. Outcome measures: Being born SGA was defined as having a birth weight below the 10th percentile for the corresponding gestational week. Preterm birth was defined as birth before the 37th gestational week. Perinatal mortality was defined as either death occurring within the first 28 days of life or stillbirth. Before 2004, fetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation, but since then stillbirth is recorded for deaths after 22 gestational weeks. Results: The authors identified 2459 pregnancies exposed to β-blockers. β-Blocker exposure during pregnancy was found to be associated with increased risk of SGA (adjusted OR 1.97, 95% CI 1.75 to 2.23), preterm birth (adjusted OR 2.26, 95% CI 2.03 to 2.52) and perinatal mortality (adjusted OR 1.89, 95% CI 1.25 to 2.84). Analyses were adjusted for socioeconomic and maternal variables. The authors found similar risk profiles for pregnancies exposed to labetalol and for pregnancies exposed to other β-blockers. Conclusions: The authors found that exposure to β-blockers during pregnancy was associated with being born SGA, preterm birth and perinatal mortality. Our findings show that labetalol is not safer than other β-blockers during pregnancy.

AB - Objective: To investigate the association between exposure to β-blockers during pregnancy and the risk of being born small for gestational age (SGA), preterm birth and perinatal mortality in a nationwide cohort. Design: A population-based retrospective cohort study, using the Danish Fertility Database. The authors identified all pregnant women redeeming a prescription for β-blockers using the National Prescription Registry. Multivariate logistic regression models were used to assess the association between exposure and our outcomes. Setting: Register-based survey. Participants: 911'685 births between 1995 and 2008 obtained from the Danish Fertility Database. Outcome measures: Being born SGA was defined as having a birth weight below the 10th percentile for the corresponding gestational week. Preterm birth was defined as birth before the 37th gestational week. Perinatal mortality was defined as either death occurring within the first 28 days of life or stillbirth. Before 2004, fetal deaths were recorded as stillbirths if they occurred after 28 weeks of gestation, but since then stillbirth is recorded for deaths after 22 gestational weeks. Results: The authors identified 2459 pregnancies exposed to β-blockers. β-Blocker exposure during pregnancy was found to be associated with increased risk of SGA (adjusted OR 1.97, 95% CI 1.75 to 2.23), preterm birth (adjusted OR 2.26, 95% CI 2.03 to 2.52) and perinatal mortality (adjusted OR 1.89, 95% CI 1.25 to 2.84). Analyses were adjusted for socioeconomic and maternal variables. The authors found similar risk profiles for pregnancies exposed to labetalol and for pregnancies exposed to other β-blockers. Conclusions: The authors found that exposure to β-blockers during pregnancy was associated with being born SGA, preterm birth and perinatal mortality. Our findings show that labetalol is not safer than other β-blockers during pregnancy.

U2 - 10.1136/bmjopen-2012-001185

DO - 10.1136/bmjopen-2012-001185

M3 - Journal article

C2 - 22815467

SN - 2044-6055

VL - 2

JO - BMJ Open

JF - BMJ Open

IS - 4

ER -

beta-blocker treatment during pregnancy and adverse preagnancy outcomes: a nationwide population-based cohort study

Abstract

Access to Document

Fingerprint

Cite this